Berkshire Hathaway, Gilead Sciences, Vertex Pharmaceuticals And A Break-Out Casino Stock Feature On CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Gilead Sciences, Inc. GILD, which has 7% free cash flow yield and a 3.6% dividend yield. "I think it will continue to be a good name to own this year," she added.

Benzinga's analyst ratings data shows GILD with a Neutral consensus rating.

Morgan Stanley recently maintained Gilead Sciences with an Equal-Weight and raised the price target from $81 to $85.

Josh Brown of Ritholtz Wealth Management named Berkshire Hathaway Inc. (NYSE: BRK-B) (NYSE: BRK-A) as his final trade.

Don’t forget to check out our premarket coverage here

Jim Lebenthal of Cerity Partners said Wynn Resorts, Limited WYNN looks like it’s breaking out right now.

Shares of casino stocks traded higher on Thursday in sympathy with Las Vegas Sands Corp. LVS, which reported better-than-expected quarterly results.

Amy Raskin of Chevy Chase Trust said Vertex Pharmaceuticals Incorporated's VRTX stock has been in a strong trend.

Vertex recently announced Health Canada market authorization for ORKAMBI in children with cystic fibrosis between ages 1 to less than 2 years of age.

Price Action: Berkshire Hathaway shares rose 0.2% to close at $323.82, while Gilead Sciences gained 0.7% to settle at $84.69 on Thursday. Vertex Pharmaceuticals gained 0.2% to $329.15, while Wynn Resorts added 1.4% to $113.69 during the session.

Check This Out: Citigroup, Dell And 2 Other Stocks Insiders Are Selling